Show simple item record

Intracranial Efficacy of Selpercatinib in Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial

dc.contributor.authorSubbiah, Vivek
dc.contributor.authorGainor, Justin F
dc.contributor.authorOxnard, Geoffrey R
dc.contributor.authorTan, Daniel S W
dc.contributor.authorOwen, Dwight H
dc.contributor.authorCho, Byoung Chul
dc.contributor.authorLoong, Herbert H
dc.contributor.authorMcCoach, Caroline E
dc.contributor.authorWeiss, Jared
dc.contributor.authorKim, Yu Jung
dc.contributor.authorBazhenova, Lyudmila
dc.contributor.authorPark, Keunchil
dc.contributor.authorDaga, Haruko
dc.contributor.authorBesse, Benjamin
dc.contributor.authorGautschi, Oliver
dc.contributor.authorRolfo, Christian
dc.contributor.authorZhu, Edward Y
dc.contributor.authorKherani, Jennifer F
dc.contributor.authorHuang, Xin
dc.contributor.authorKang, Suhyun
dc.contributor.authorDrilon, Alexander
dc.date.accessioned2021-06-21T15:23:33Z
dc.date.available2021-06-21T15:23:33Z
dc.date.issued2021-06-18
dc.identifier.urihttp://hdl.handle.net/10713/16059
dc.description.abstractWe report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for RET fusion-positive non-small cell lung cancers (NSCLC).en_US
dc.description.urihttps://doi.org/10.1158/1078-0432.CCR-21-0800en_US
dc.language.isoenen_US
dc.publisherAmerican Association for Cancer Researchen_US
dc.relation.ispartofClinical Cancer Researchen_US
dc.rights©2021 American Association for Cancer Research.en_US
dc.subjectLIBRETTO-001 Trialen_US
dc.subjectRET fusion-positive NSCLCen_US
dc.subjectselpercatiniben_US
dc.subject.meshCarcinoma, Non-Small-Cell Lung--drug therapyen_US
dc.titleIntracranial Efficacy of Selpercatinib in Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trialen_US
dc.typeArticleen_US
dc.identifier.doi10.1158/1078-0432.CCR-21-0800
dc.identifier.pmid34088726
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record